Domain Therapeutics is a private biopharmaceutical company based in Montreal, Canada and Strasburg France. The company has a best-in-class GPCR discovery platform, BioSensALL, that is highly validated through multiple industry partnerships. The company is advancing multiple assets into the clinic, including a best-in-class anti-CCR8 antibody and a PAR2 antagonist.
Solid tumors
CTI LSF III
Co-Lead
Director
March 17, 2022
Active
Series A
Domain’s unique platform produced potential best-in-class assets against valuable GPCR targets, its lead assets demonstrated best-in-class data in the pre-clinical setting
January 5, 2023
January 5, 2023
June 29, 2023
June 29, 2023
